Free shipping on all orders over $ 500
FHD-286 is the first dual inhibitor of SMARCA2/SMARCA4. , can be used for metastatic melanoma and advanced hematological tumor research.
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Molecular Weight | 562.66 |
| Formula | C24H30N6O6S2 |
| CAS Number | 2671128-05-3 |
| Purity | N/A |
| Solubility | ＞10 μM for FaSSIF |
| Storage | at -20°C |
| Related Epigenetic Reader Domain Products |
|---|
| MI-3
Mi-3 (Menin-mLL inhibitor 3) is an effective and high affinity menin-MLL inhibitor with IC50 value of 648 nM and Kd value of 201 nM. |
| Alobresib
Alobresib (GS-5829) is a BET bromine domain inhibitor that can be used in the study of recurrent and drug-resistant overexpressed c-Myc uterine serous carcinoma. |
| ZL0420
ZL0420 is a potent and selective BET bromine domain 4 (BRD4) inhibitor of BRD4 BD1 and BRD4 BD2 IC50 27 nM and 32 nM, respectively. |
| MS645
MS645 is a BET bromodomains (BrD) inhibitor for K of BRD4-BD1/BD2i The value is 18.4 nM. MS645 spatially limits the divalent inhibition of BRD4 BrDs, resulting in sustained inhibition of BRD4 transcriptional activity in solid tumor cells. |
| LT052
LT052 is a highly selective BET BD1 inhibitor IC50 87.7 nM. LT052 exhibits nanomolar-grade inhibitory activity of BRD4 BD1 and is 138 times more selective than BRD4 BD2 (IC).50=12.130 μM)。 LT052 has anti-inflammatory activity and can be used in acute gouty arthritis studies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
